Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD19 AbTCR-expressing T lymphocytes EB103

A preparation of autologous T lymphocytes transduced with a lentiviral vector encoding an antibody-T-cell-receptor (AbTCR) composed of a CD19-binding domain derived from an antibody fragment antigen binding (Fab) region and an effector domain derived from human gamma/delta TCR, and a co-stimulatory molecule composed of a CD19-binding domain derived from a single-chain variable fragment (scFv) and a co-stimulatory domain derived from a human co-stimulatory receptor, with potential immunostimulating and antineoplastic activities. Upon administration of the autologous anti-CD19 AbTCR-expressing T lymphocytes EB103, both the AbTCR moiety and the co-stimulatory molecule recognize and bind to CD-19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies.
Synonym:autologous anti-CD19 AbTCR-expressing T cells EB103
autologous anti-CD19 antibody redirected T cells with endogenous modular immune signaling EB103
autologous CD19-redirected ARTEMIS T cells EB103
Code name:EB 103
EB-103
EB103
Search NCI's Drug Dictionary